JO
TEVA icon

John Overdeck’s Teva Pharmaceuticals TEVA Stock Holding History

John Overdeck’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$817K Buy
+24,100
New +$803K ﹤0.01% 3767
2026
Q1 		– Sell
-23,000
Closed -$718K – 4921
2025
Q4 		$718K Buy
+23,000
New +$567K ﹤0.01% 3121
2021
Q4 		– Sell
-170,000
Closed -$1.66M – 4882
2021
Q3 		$1.66M Buy
170,000
+124,400
+273% +$1.16M ﹤0.01% 2159
2021
Q2 		$451K Sell
45,600
-15,700
-26% -$166K ﹤0.01% 3192
2021
Q1 		$707K Buy
+61,300
New +$703K ﹤0.01% 2624
2020
Q4 		– Sell
-25,300
Closed -$228K – 3757
2020
Q3 		$228K Sell
25,300
-11,500
-31% -$122K ﹤0.01% 2746
2020
Q2 		$454K Sell
36,800
-56,400
-61% -$638K ﹤0.01% 2066
2020
Q1 		$837K Sell
93,200
-449,300
-83% -$4.6M 0.01% 1550
2019
Q4 		$5.32M Buy
542,500
+466,300
+612% +$4.16M 0.02% 915
2019
Q3 		$524K Sell
76,200
-76,700
-50% -$588K ﹤0.01% 2520
2019
Q2 		$1.41M Buy
152,900
+123,700
+424% +$1.49M ﹤0.01% 1674
2019
Q1 		$458K Buy
+29,200
New +$515K ﹤0.01% 2320
2018
Q4 		– Sell
-62,900
Closed -$1.35M – 3516
2018
Q3 		$1.35M Sell
62,900
-21,400
-25% -$497K ﹤0.01% 1763
2018
Q2 		$2.05M Sell
84,300
-146,400
-63% -$2.99M 0.01% 1598
2018
Q1 		$3.94M Buy
230,700
+155,100
+205% +$3.03M 0.01% 1090
2017
Q4 		$1.43M Buy
75,600
+59,200
+361% +$891K ﹤0.01% 1713
2017
Q3 		$289K Sell
16,400
-29,600
-64% -$666K ﹤0.01% 2434
2017
Q2 		$1.53M Sell
46,000
-94,400
-67% -$2.92M 0.01% 1605
2017
Q1 		$4.5M Buy
+140,400
New +$4.79M 0.02% 982
2016
Q4 		– Sell
-152,700
Closed -$7.03M – 3507
2016
Q3 		$7.03M Buy
152,700
+146,700
+2,445% +$7.65M 0.03% 708
2016
Q2 		$301K Hold
6,000
– – ﹤0.01% 2558
2016
Q1 		$321K Buy
6,000
+1,900
+46% +$111K ﹤0.01% 2347
2015
Q4 		$269K Buy
+4,100
New +$253K ﹤0.01% 2308

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

John Overdeck's TEVA Position: Q2 2026 in Review

John Overdeck reduced its Teva Pharmaceuticals (TEVA) stake by 37% in Q2 2026, selling an estimated $4.51M and leaving 231,287 shares worth $7.84M. The position accounts for 0.01% of the portfolio, ranked #1717.

John Overdeck first reported a position in TEVA in Q2 2013 and has held it in 49 quarters since. The position peaked at $142M in Q4 2016. 671 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • John Overdeck held 231,287 shares of Teva Pharmaceuticals worth $7.84M as of Q2 2026.
  • John Overdeck sold 135,504 Teva Pharmaceuticals shares in Q2 2026, an estimated $4.51M.
  • Teva Pharmaceuticals made up 0.01% of John Overdeck's portfolio in Q2 2026, its #1717 holding.
  • John Overdeck first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 49 quarters since.
  • John Overdeck's Teva Pharmaceuticals position peaked at $142M in Q4 2016.
  • 671 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.